Although lay health workers (LHWs) improve cancer screening and treatment adherence, evidence on whether they can enhance other aspects of care is limited.
C linical advances have transformed cancer care; however, the delivery of high-quality end-of-life care remains a considerable challenge. [1] [2] [3] Few patients understand their prognosis, 4,5 and many receive care that differs from their documented preferences. 1, 6, 7 These gaps are compounded by rising cancer care costs, 8, 9 with almost half of total Medicare expenditures in the last year of life spent in patients' final month. 9, 10 Communication between patients and physicians regarding prognosis and end-of-life care preferences improves care 1, 6, 11, 12 and lowers costs 13 ;h o wever, clinicians have limited time 14 and may be reluctant [14] [15] [16] to engage in or document these discussions. Although palliative care clinicians can assist, 17 their numbers, and therefore time, are also limited. 18 Therefore, other strategies may be needed to ensure that patients understand and communicate their end-of-life care choices to their families and health care providers.
14, [18] [19] [20] Internationally, nonclinical, nonprofessional personnel trained in specific skills assist in delivering a variety of services, including end-of-life care. 21 These personnel are often called lay health workers (LHWs) but known by more than 60 different names worldwide. 22 Lay health workers have been a part of the US health care workforce since the mid-1960s.
23
Professional resource shortages and novel payment models have reinvigorated interest in LHW programs, 24,25 with a projected 13% increase in LHW employment by 2024.
26
Although LHWs aid in cancer screening and treatment adherence, 27 they are infrequently integrated into end-oflife care, 14, 20, [28] [29] [30] [31] and few randomized trials have evaluated their effectiveness in this setting. 31 We conducted a randomized study among patients with advanced-stage cancer to evaluate the effects of an LHW intervention on documentation of patients' end-of-life care preferences (goals of care), patient satisfaction, health care use, and total health care expenditures.
Methods

Study Design and Oversight
We conducted a 2-arm, randomized quality improvement study at the Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto, California, from August 13, 2013 , to February 2, 2015 . In 2013, the Stanford University Institutional Review Board and VAPAHCS Research and Development Committee determined that the protocol was quality improvement. In 2016, both boards approved the retrospective evaluation of the program's effectiveness on patient satisfaction, health care use, and health care expenditures as a clinical trial (the trial protocol is available in Supplement 1). Despite the quality improvement designation, all participants provided written informed consent.
Study Participants
Patients older than 18 years with newly diagnosed stage 3 or 4 solid tumors or those with recurrent disease were eligible to participate. Patients who did not plan to receive oncology care at VAPAHCS were excluded. Participants were randomized in a 1:1 ratio stratified by cancer diagnosis (eTable 1 in Supplement 2) to 1 of 2 strategies: an LHW program integrated with usual care (intervention arm) or usual care alone (control arm). The flow of participants through the study is shown in the Figure and in eFigure 1 in Supplement 2.
Usual Care
All participants received usual care provided by the oncology team, a social worker who arranged housing and transportation, and a behavioral medicine practitioner who provided mental health counseling.
LHW Intervention
We hired 1 LHW with a bachelor of arts degree who was enrolled in a part-time graduate health education program. We trained the LHW using a curriculum developed by the principal investigator (M.I.P.) and informed by social cognitive theory. 32 The training included an 80-hour online skillsbased seminar 33 and a 4-week observation training with the VAPAHCS palliative care team (eAppendix in Supplement 2). The intervention consisted of a 6-month structured program with the LHW, who assisted patients with advance care planning, including (1) education on goals-of-care principles; (2) establishing care preferences; (3) identifying a surrogate decision maker; (4) filing an advance directive; and (5) encouraging patients to discuss care preferences with providers. The LHW addressed these topics in an initial 30-minute telephone conversation with the patient within 2 weeks after randomization and then reassessed preferences in subsequent 15-minute, twice-monthly conversations by telephone or in person for 6 months after randomization or until patient death, whichever came first. The LHW was employed 20 hours weekly, supervised on-site by a registered nurse, addressed goals of care only, and had no direct interaction with the clinical oncology team. All clinical concerns raised by patients were discussed with the supervising registered nurse.
Blinding
The principal investigator (M.I.P.), oncology clinicians (excluding the supervising registered nurse), and data abstractors were blinded to the participant's randomization assignment.
Outcomes
The primary outcome-whether an oncology clinician documented patients' end-of-life care preferences in a clinical note in the electronic health record (EHR) within 6 months of randomization-was intended to measure whether the intervention encouraged patients to discuss goals of care with oncology providers. The objective was to achieve goals-of-care documentation among at least 75% of patients. Prespecified secondary outcomes (defined below) included advance directive documentation, patient satisfaction, health care use, and costs.
Patient Satisfaction Measures
We measured satisfaction with care when patients were randomized into the program (baseline) and again 6 months after randomization using the "satisfaction with provider" item (question 18) of the validated Consumer Assessment of Healthcare Providers and Systems General Survey. 13, 34 We directed patients to answer this question in regard to their oncology provider on a scale of 0 to 10, where 0 is the worst and 10 is the best possible satisfaction. We assessed satisfaction with decision making within 4 to 6 months of randomization using the validated 6-item Satisfaction With Decision Scale 35 on a scale ranging from 0, indicating no satisfaction, to 5, indicating maximum satisfaction. A clinically meaningful difference in the Satisfaction With Decision scale is 0.5 35 and in the satisfaction with provider scale is 0.9. 36 A trained research assistant, blinded to the randomization, administered assessments by telephone.
Health Care Use and Cost Measures
We followed up all patients for 15 months or until death. Based on national survival statistics, we estimated that half of the participants would have died within 15 months. 37 We measured health care use and cost outcomes at 6 months after randomization and measured a subset of outcomes again at 15 months after randomization. We collected the use and dates of the following from the EHR: chemotherapy, surgery, and radiotherapy use, VA and non-VA emergency department (ED) use, hospitalizations, inpatient and outpatient palliative care visits, and hospice service use. For ED visits and hospitalizations, we measured whether patients had any use and the frequency of use. We measured chemotherapy, surgery, and radiotherapy use based on any use within the 6-month postrandomization period. We measured all other health care use within the 6-and the 15-month postrandomization periods. Total health care costs for VA and non-VA care were provided by the VAPAHCS Decision Support System office, VA Allocation Resource Center, and the VAPAHCS Office of Business Analytics and reported for the 6-month period before randomization for each participant (to test whether patients had similar costs of care before study enrollment) and for the 6-and 15-month postrandomization periods. We obtained date of death from the EHR to assess survival, health care use, and total health care costs within 30 days before death 38 for the subset of patients who died within 15 months after randomization. We followed up all patients through April 6, 2016, and collected health care use data and total health care costs through December 6, 2016, to account for an 8-month lag time in non-VA facility claims.
Demographic and Clinical Characteristics
We collected the following additional data from the EHR: age, sex, cancer diagnosis and stage, new diagnosis or recurrent cancer, 1-way travel distance from patient residence to VAPAHCS, and advance directive documentation. Patients selfreported their race/ethnicity and marital status.
Statistical Analysis
We calculated that a sample of 105 patients in the program would provide 80% power and a 2-sided α level of .05 to detect an increase in goals of care documentation from 57%, based on previously reported data among patients with cancer in another VA facility, 39 to 75% within 6 months after randomization. We analyzed the program's effect on primary and secondary outcomes on an intention-to-treat basis after adjusting all analyses for anatomic site of cancer diagnosis. We used logistic regression to compare differences between the 2 groups for dichotomous outcomes (goals-of-care documentation, advance-directive documentation, any palliative care, any hospice, any chemotherapy, any radiotherapy, any surgery, any ED visit, and any hospitalization). We compared ED visits and hospitalizations per patient by using exact Poisson regression models, with an offset term for length of follow-up. We compared total health care costs by using a generalized linear model with a gamma link-log function to account for skewed data, with an offset term for length of follow-up. To analyze satisfaction, we used generalized linear regression to compare the change in satisfaction with care from baseline between study arms by using a repeated-measures analysis of variance model. Patient satisfaction observations that were missing owing to death or nonresponse were dropped from the patient satisfaction analysis. We compared survival by using Kaplan-Meier methods and risk of death by using Cox proportional hazards regression models. We conducted all significance testing at a 2-sided P value of .05 and performed all statistical analyses from January 15 to August 18, 2017, with SAS, version 9.3 (SAS Institute Inc).
Results
A total of 213 patients were enrolled. The mean (SD) age of participants was 69.3 (9.1) years, and 211 (99.1%) were male. Of this cohort, 165 (77.5%) reported being of non-Hispanic white race/ethnicity, 11 (5.2%) were non-Hispanic black, 7 (3.3%) were Asian/Pacific Islander, 4 (1.9%) were Hispanic, 4 (1.9%) were Native American/Native Alaskan, and 9 (4.2%) were of another race/ethnicity. One hundred five participants were randomized to the intervention and 108 to the control arm (eFigure 1 in Supplement 2). Three patients died after randomization but before enrollment, 2 patients were randomized but could not be contacted, and 5 patients withdrew from the study at the 6-month follow-up visit. All 213 were included in the intention-to-treat analysis for health care use and cost outcomes. There were no statistically significant differences between the groups in demographic or clinical characteristics, satisfaction with health care, or total health care costs in the 6-month period before randomization (eTable 1 in Supplement 2). 
Goals of Care and Advance Directive
Patient Satisfaction
Patients in the intervention arm were more satisfied with their decision making and care than patients in the control arm ( a For all variables, 2-sided P < .001.
b
The P values were estimated using logistic regression models after adjustment for cancer site.
c Satisfaction with decision was assessed with the use of the 6-item Satisfaction With Decision Scale
35
; scores range from 0 to 5, with higher scores indicating better satisfaction. In all, 77 patients (71.3%) in the control arm and 80 (76.2%) in the intervention arm completed this survey between 4 and 6 months after study enrollment; 25 patients in the control arm and 22 in the intervention arm had died at the time of this assessment. The P values were estimated using generalized linear regression models after adjustment for cancer site.
d Satisfaction with care was assessed with the use of the Consumer Assessment of Healthcare Providers and Systems-General Survey 34 question 18, which measured rating of health provider; scores range from 0 to 10, with higher scores indicating higher ratings. In all, 60 patients (55.6%) in the control arm and 58 (55.2%) in the intervention arm completed this survey at 6 months after study enrollment; 36 patients in the control arm and 36 in the intervention arm had died at the time of this assessment. The P value was estimated using generalized linear regression models after adjustment for cancer site.
e The P value was estimated using a repeated-measures analysis of variance model after adjustment for cancer site.
Health Care Use and Total Health Care Costs
Rates of intensive cancer treatments (chemotherapy, radiotherapy, and surgery) within 6 months of randomization were similar between the groups. Patients in the intervention arm were more likely to have used hospice services within both 6 and 15 months of randomization (6 months 
Discussion
This single-center, randomized study within the VA demonstrates that integrating an LHW into usual cancer care is an effective strategy for increasing goals-of-care documentation among patients with stage 3 or 4 cancer or recurrent cancer. The intervention resulted in greater patient satisfaction with care and decision making, higher rates of hospice use, lower acute care use, and lower total health care expenditures at the end of life without adversely affecting survival.
Although new initiatives encourage clinicians to discuss and document their patients' goals of care, 40 less than half of the patients in the United States with terminal illnesses have their end-of-life wishes documented. 41 We provide evidence that an LHW trained to assist with end-of-life care integrated into usual cancer care can effectively address this deficiency. Our intervention, comprising up to 6 months of engagement with an LHW by telephone or in person, increased documentation of goals of care 5-fold and advance directives nearly 3-fold and nearly doubled hospice use within 6 months of enrollment. The intervention also substantively changed endof-life care, with a nearly 6-fold reduction in ED and hospital use, nearly 2-fold increase in hospice use, and a 95% reduction in total health care spending in the final month of life among patients who died within 15 months of enrollment, supporting the long-lasting effect of the intervention. Although our study does not explain why the LHW was effective, it is possible that the LHW conveyed information about goals of care and advance directives in a way that was more easily accepted by patients and their families 42, 43 and that the LHW had more time than medical professionals to encourage patients to frequently assess their end-of-life care choices and proactively communicate their preferences to their clinical teams. The improved documentation of patients' end-of-life care preferences, such as do not resuscitate and do not intubate, may have also prompted oncology providers to discuss hospice earlier. Despite the significant increase in hospice use, the intervention did not increase palliative care use, possibly reflecting the limited accessibility of outpatient palliative care services in this setting. We found that reductions in cost associated with the intervention occurred primarily at the end of life. Although we targeted patients who had a high likelihood of death, approximately one-third of patients died within 6 months a Calculations are based on the sample of the 60 patients in the control arm and the 60 patients in the intervention arm who died within 15 months of study enrollment. All P values are 2-sided.
b The P value was estimated using the χ 2 test.
c The P value was estimated using the exact Poisson regression model after adjustment for cancer site and offset for duration of follow-up.
d The P value was estimated using logistic regression model after adjustment for cancer site.
e The P value was estimated using a generalized linear model with gamma link-log function to account for skewed cost data after adjustment for cancer site and offset for length of follow-up. and slightly more than half of patients died within 15 months of enrollment. Correspondingly, the reduction in total health care costs associated with the intervention increased between 6 and 15 months as more patients reached the end of life, although the difference between the intervention and control arms was not significant at either point. Our small sample size may have limited the ability to see differences in costs at 15 months after randomization because the study was not powered to detect cost differences. It is possible, however, that as more patients reach the end of life, the potential for having had their end-of-life care preferences documented increases; thus, the intervention generates even greater cost reductions. Our large and statistically significant reductions in ED use and hospitalizations within 30 days of death are consistent with this interpretation. Future research should include a longer follow-up period to determine whether these results persist for patients with longer survival. Our study differed in important ways from earlier studies. First, the LHW in our study assisted patients only with goals of care. In other studies, either clinicians 44, 45 or lay personnel 28 were also involved in other aspects of care, including care coordination and symptom management. Furthermore, a previous intervention that used lay personnel directly embedded the intervention in oncology care and provided the intervention for a longer duration, whereas ours lasted 6 months and did not require the LHW to interact with oncology clinicians. 28 Finally, our intervention, which was intensely and narrowly focused on advance care planning, achieved substantively larger cost reductions. 46 Although we did not conduct a formal cost-benefit analysis, it is likely the reduction in health care spending exceeded the intervention's implementation costs. Our intention-to-treat analysis estimates that the intervention reduced total health care costs by approximately $31 660 per patient in the intervention resulting in an overall savings of $3 324 300 ($31 660 multiplied by 105 patients) during the 15-month study. The total costs associated with the intervention implementation, including training and labor costs, were $20 368. Thus, the net savings associated with the program were approximately $3 303 932, equivalent to a 20% reduction in total health care spending.
(eAppendix in Supplement 2).
Limitations
The study had some limitations. First, the study was limited to 1 VA institution and a single LHW for a predominantly older, nonHispanic white male population, potentially limiting the generalizability of our findings to members of racial/ethnic minority groups and younger patients. Although we expect more room for improvement in other systems, understanding the potential of the LHW program outside the VA will require further investigation. Second, because the study was conducted at the patient level, there could be contamination: the oncologists' practice patterns may have changed given that patients in the intervention prompted them to discuss goals of care. The low rates of goals-of-care documentation among patients in the control arm, however, suggest that this is unlikely to be the case. Finally, we did not have a sufficient sample size to analyze differences across cancer stages or diagnoses.
Conclusions
Our results demonstrate that an LHW, when integrated into cancer care, can improve patient satisfaction and reduce health care use and costs. Given recent trends toward reimbursement models that reward high-value care delivery, LHWs may represent one solution, through greater discussion and documentation of care preferences, to more broadly address patients' preferences and mitigate unwanted, burdensome, and costly care at the end of life. Although our intervention may be a promising approach to improving end-of-life care delivery for patients with cancer, further research is needed to assess the generalizability of this approach for patients in other settings and with other near-terminal, serious illnesses.
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Disclaimer
The Effect of A Lay Health Worker Intervention on End of Life Cancer Care: Evaluation of the Engagement of Patients with Advanced Cancer (EPAC) Program
SPECIFIC AIMS
Aims
The primary aim is to evaluate the effect of integrating a Lay Health Worker (LHW) into oncology care after a diagnosis of advanced cancer or recurrent and progressive disease on percent of patients with documentation of goals of care conversations by oncologists in the electronic health record.
Secondary aims are to assess the effect of the intervention on: 1. Patient satisfaction with decision-making and healthcare 2. Utilization of healthcare resources 3. Total Healthcare costs 4. End-of-life care (30 days prior to death) utilization and costs for subset of patients who died within 6-months and 15-months post-randomization
Hypotheses
Primary Hypothesis: The lay health worker (LHW) program will result in documentation of goals of care conversations by oncologists of at least 75% for patients in the intervention within 6 months of enrollment in the study.
Secondary Hypotheses (to obtain effect sizes): Compared to patients who receive usual oncology care, patients in the program will experience improved satisfaction with decision and healthcare, lower rates of acute care utilization and total healthcare costs at 15-months postrandomization, and lower rates of acute healthcare utilization and lower total healthcare costs at the end-of-life (last 30 days of life).
PROGRAM ENROLLMENT AND PARTICIPANT ELIGIBILITY
Enrollment
Location
Veterans were recruited from the Oncology clinics at the VA Palo Alto Health Care System (VAPAHCS) from August 2013-February 2015.
Enrollment Procedures
Each week, the site PI and program coordinator reviewed the list of patients scheduled for clinic appointments for the upcoming month. Please see previous protocol (version 6.0 Date: 8-11-2013) for details of the program enrollment, screening, and consent procedures.
Participant Criteria
Inclusion criteria
1. Newly diagnosed patients with stage 3 and 4 solid tumors.
2. Patients with recurrent or progressive disease as identified by imaging or biopsy and confirmed by physician.
3. The patients had to be 18 years or older.
Exclusion Criteria 1. Patients who did not have the ability to understand and/or willingness to sign a written informed consent document.
2. Patients who did not plan to receive all of their oncology care at the VAPAHCS (i.e. second opinion referrals).
Criteria for Removal from Study
Any patients or families of patients in the program arm who withdrew consent were removed from the project. Upon removal, usual care was restored for these patients.
Enrollment Sample
The target number of subjects at the site was approximately 210 (105 per arm) stratified by anatomic site of cancer diagnosis. A total of 213 patients were enrolled in the program with 105 in the lay health worker program arm and 108 in the usual cancer care arm. Data collection occurred at months 6 and 15 after patient enrollment. The data follow-up period occurred for up to 15 months following enrollment for each patient or death (whichever was first).
MATERIALS AND METHODS
We will use the electronic health record to abstract all relevant variables. As part of the project, a project chart was created for each patient. Patients were assigned a program identification number for all survey data and assessments as outlined in the protocol version 6.0 date: 8-11-2013. This identification number will be used on all subject-specific documents and researchrelated forms.
All patients were assigned to two arms as listed below.
All patients were surveyed during the program by a blinded, trained research assistant regarding patient satisfaction with healthcare (using the Consumer Assessment of Healthcare Providers and Systems Ð General survey) at baseline (at time of enrollment) and again at month 6 after enrollment. All patients were surveyed regarding patient satisfaction with decision-making Arm B: EPAC (LHW Intervention)/ Intervention Group The program was comprised of a lay health worker assignment with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the lay health worker after the first oncology appointment to discuss goals of care within 2 weeks of enrollment in the study. The lay health worker underwent standardized training with additional supervised visits to learn how to engage patients and families in goals discussions (see Training Details below).
The lay health worker contacted patients based on ongoing needs. Lay health worker also conducted meetings with patients, their families, and/or caregivers after an emergency department visit, hospitalization, change in treatment, or unexpected symptom. (The intervention details are provided in the attached Protocol Appendix B).
Patients in the lay health worker program received a two-question assessment of their satisfaction with and likelihood to recommend the care provided by the LHW. The two questions were measured on a scale that ranges from 0 indicating no satisfaction and 5 indicating maximum satisfaction.
Protocol Director: Dr. Patel Dr. Patel, PI of the program, is responsible for the overall study including corresponding with the site PI to help troubleshoot any challenges in data collection or follow-up.
STATISTICAL CONSIDERATIONS
Biostatistician: Manisha Desai PhD (Stanford University) and Vandana Sundaram MPH (Stanford University). They will be responsible for providing randomization assignment for patients and analyzing the data.
Outcome Measurements
None of the listed outcomes relate to safety:
Primary Outcome Measure Measurement of documentation of goals of care conversations by oncologists in the Electronic Health Record. This includes any mention of patientsÕ care preferences. Hypothesis: 75% of patients in the lay health worker program with documentation of their goals of care and preferences for care within 6 months after enrollment.
Secondary Outcome Measure
Utilization will be evaluated by comparing hospitalizations, emergency department, palliative care referral and consultation, hospice referral and consultation at 6-months post-randomization and 15-months post-randomization, and, for those patients who died at 6-and 15-months postrandomization, 30 days prior to death between the two program groups. We will assess utilization of chemotherapy, radiation, and surgery at 6 months post-enrollment. Total healthcare costs for VA care will be obtained from the VA Palo Alto Decision Support System office and the VA Allocation Resource Center. Total healthcare costs for non-VA care (actual cost paid to non-VA providers) will be obtained from the VA Palo AltoÕs Office of Business Analytics.
All patients enrolled in the project will be used for the analysis for an intention to treat analysis.
Secondary outcomes also include differences in satisfaction with healthcare and differences in decision-making.
Sample Size
A total of 105 patients in the program arm was needed to attain significant differences from empiric evidence within 6 months after study enrollment for patients in the intervention of our primary outcome, documentation of goals of care. Sample size is not powered to detect differences in our pre-specified secondary outcomes which include: patient satisfaction, healthcare utilization, and total healthcare. For all secondary outcomes, we will obtain effect sizes and report the results descriptively.
Data Variables and Analysis
Satisfaction with care was measured when patients were randomized into the program versus the control arm (baseline) and again 6 months after randomization using the validated Consumer Assessment of Healthcare Providers and Systems Ð General survey. Satisfaction with decisionmaking was assessed for all study participants between 4 and 6 months after randomization using the validated 6-question Satisfaction with Decision Scale on a scale ranging from 0, indicating no satisfaction, to 5, indicating maximum satisfaction. A trained research assistant, blinded to the randomization, administered all satisfaction measures telephonically. All responses were entered into the patientÕs program chart and all data will be abstracted and analyzed from the program chart into a de-identified study database.
The use of the following services for each patient in the program arm and control arm will be collected: chemotherapy, surgery, and radiation utilization, Veterans Administration (VA) and non-VA emergency department (ED) use and hospitalizations, inpatient and outpatient palliative care, and hospice consultation.
Chemotherapy, surgery, and radiation utilization will be measured for all program patients within the 6-month period after randomization. All other healthcare utilization will be measured within the 6-and 15-month period after randomization. The date of death will also be collected from the electronic health record and where missing will be collected from the cancer registrars. ED use, hospitalizations, and hospice use within 30 days of death will be measured for the subset of patients who died within 6-and 15-months post-randomization. Total healthcare costs for VA and non-VA care will be collected by the VA Palo Alto Decision Support System office, the VA Allocation Resource Center and the VA Palo AltoÕs Office of Business Analytics, and measured during the 6 months prior to randomization for each participant (to test whether patients had similar costs of care prior to their enrollment in the study) and for the 6-and 15-month period after randomization and total healthcare costs will be collected for the 30 days prior to death for the subset of patients who died within 6-and 15-months follow-up. We will measure survival at the 6-and 15-months period after randomization. All patients will be followed through April 6, 2016. Health care utilization and total healthcare costs will be collected through December 6, 2016 to account for an 8-month lag time in service claims from non-VA facilities. We will also collect the following data: age at diagnosis and enrollment in the program, sex, cancer diagnosis and stage, new diagnosis or recurrent cancer, and travel distance to the VAPAHCS.
Statistical Analyses
We will use logistic regression models to compare difference between the two groups for dichotomous outcomes.
We will compare the total number of ED visits and hospitalizations using exact Poisson regression models with an offset term for length of follow-up.
We will use generalized linear models to account for skewed cost data and to compare changes in satisfaction with care between study arms from baseline using ANOVA.
We will compare survival using Kaplan Meier methods and the risk of death for the two groups after randomization using Cox proportional hazards regression models. For patients who died, we will compare the number of ED visits and hospitalizations in the last 30-days of life, proportion of patients who were enrolled in hospice at the time of death, and total healthcare costs in the last 30 days of life using the models described above. All significance testing will be conducted at a two-sided p-value of 0.05. Statistical analyses will be performed with SAS.
DATA MANAGEMENT CONSIDERATIONS
Data Management
All data will be kept on a secure server. All paper surveys collected during the original program enrollment will be transcribed into a database with only a subject identification number that is coded without any patient identifiers. The code will be kept in a locked file in a locked room and only accessible to the study PI and staff listed. The PI and participating site investigators will maintain adequate and accurate participant case histories with observations and other data.
Original source documents will be transcribed to data collection tools and used to communicate and analyze study data.
The site PI will be responsible for maintaining the clinical protocol and subjectsÕ program charts and reporting the status of the program in continuing renewals or amendments submitted to their IRB per facility protocol.
Confidentiality
Members of the local team will be responsible for database records of patient data. The data will be kept in the secure central online study database under password protection, encrypted, and with access limited to specific areas of the database. A chart with all of the relevant research patient information will be maintained at the VA. The Study Coordinator may review patient charts for yearly audits.
Protocol Review and Amendments
The protocol, the proposed informed consent and all forms of participant information related to the program (e.g. advertisements used to recruit participants) will be reviewed by the Stanford IRB. Any changes made to this protocol will be submitted as a modification and will be approved by the IRB. The Protocol Director will disseminate the protocol amendment information to all participating investigators.
APPENDIX A: DETAILS OF INTERVENTION
Details of the LHW intervention The LHW intervention is designed to improve knowledge, beliefs, values, attitudes and confidence through social support, multimedia education and skills building provided by LHWs to engage in early advance care planning and discussing their care preferences (goals of care) with their providers.
Patients in the intervention arm will receive a 30 minute phone call from the LHW after patient consents and within 2 weeks of randomization into the study for study participation to establish rapport and discuss the importance of early advance care planning.
After the discussion, the LHW will mail a new patient packet that includes advance care planning multi-media educational materials, including an educational brochure from the website Prepareforyourcare.org and a blank VA advance directive form. Thereafter, the LHW will conduct twice monthly 15-minute telephonic or in-person conversations for 6 months after study enrollment or until patient death, whichever is first. In these twice monthly interactions, the LHW will educate patients on principles of goals of care and advance care planning, assist patients in their advance care planning, establishing their preferences for care, identifying their surrogate decision-maker, filing advance directives, and activating them to discuss their care preferences and advance directive with their oncology providers. The LHW will revisit these activities when treatment plans change or if patients experience unexpected emergency department visits or hospitalizations. The LHW will be supervised on-site and meet weekly with a registered nurse to discuss all patient cases.
Recruitment, Retention and Training LHW We will work with the VAPAHCS facility to post an opening for a LHW to be employed for this study. We expect to hire a LHW with no previous medical experience but who is familiar with the VAPAHCS facility and procedures. We have created a LHW training program that includes multimedia didactic, skills-building training drawing from cancer navigation and palliative care. The LHW will participate in an 80 hour-online skills-based training and a 4-week in-person observation training led by the facilityÕs palliative care team. Online training activities include 15-content modules in a multi-media internet-based course focused on delivering successful end-of-life care for older adults relationship-building, challenges at the end-of-life, and tools to improve engagement of patients in advance care planning (Stanford UniversityÕs Internet based Successful Aging (iSAGE) https://aging.stanford.edu/isage-mini-fellowship-overview/). The 4-week in-person training will include: a didactic series focused on challenges in health communication, importance of social support, self-efficacy, and skills-based knowledge and supervised practice to improve patientsÕ engagement in early advance care planning. The LHW will be employed 20 hours a week and expected to provide services to 75 patients per week.!! 
LHW Intervention and Training Details
LHW Training
The LHW Training was framed by the Social Cognitive Theory which explains the LHW-patient relationship and its links to self-efficacy, through social support, knowledge, and skills, to engage in early advance care planning (behavior change). The Social Cognitive Theory outcomes include engagement in behavior change (i.e. early advance care planning).
